Retatrutide Research
Retatrutide CAS Number and Chemical Identity
Retatrutide's CAS Registry Number is 2381089-83-2. It is also indexed on PubChem and referenced as LY3437943 in Eli Lilly filings. Its molecular formula reflects a 39-residue peptide with C20 diacid fatty-acid conjugation and approximate molecular weight of 4,731 Da.
Key facts
- CAS Number
- 2381089-83-2
- Internal code
- LY3437943
- Molecular weight
- ~4,731 Da
- Class
- Synthetic peptide
How to verify chemical identity
Research-grade retatrutide should ship with a Certificate of Analysis showing HPLC purity and mass-spectrometry confirmation of the expected mass (~4,731 Da). CAS number matching is a first-pass identity check only.
Extended research context
The Retatrutide Research deep dive
Deep dive: how the triple-agonist scaffold was engineered
Retatrutide's 39-residue backbone was designed by Eli Lilly's peptide chemistry team to preserve the pharmacophores of three glucagon-family receptors on a single chain. The N-terminal domain retains GIP-receptor contacts, mid-chain substitutions restore GLP-1-receptor affinity lost in native GIP, and additional residue swaps confer glucagon-receptor engagement. A γGlu-2xOEG linker anchors a C20 fatty diacid at Lys17, which reversibly binds serum albumin and slows renal clearance — the same albumin-tethering strategy Novo Nordisk pioneered with semaglutide and Lilly refined further in tirzepatide.
The TRIUMPH Phase 3 programme in context
TRIUMPH is Lilly's global Phase 3 development umbrella for retatrutide, spanning obesity (TRIUMPH-1 through TRIUMPH-4), type 2 diabetes, MASH (metabolic dysfunction-associated steatohepatitis), and knee osteoarthritis linked to obesity. Readouts began in 2025 and continue through 2026. Because the compound is investigational, no regulator — FDA, EMA, or MHRA — has issued marketing authorisation, and legitimate supply exists only for laboratory reference and research contexts, never for human administration.
How retatrutide differs from tirzepatide and semaglutide at the mechanism level
Semaglutide is a mono-agonist (GLP-1 only). Tirzepatide is a dual agonist (GIP + GLP-1). Retatrutide adds glucagon-receptor activity, which pre-clinical and Phase 2 data suggest contributes to energy expenditure in addition to appetite regulation and glucose-dependent insulin release. This three-receptor combination is why retatrutide is sometimes called a 'metabolic multi-tool' peptide in the trade press — but the pharmacology is more nuanced than the label implies.
Research applications
- ▸In vitro receptor-binding assays across GIP-R, GLP-1R and GCGR panels
- ▸Comparator studies alongside semaglutide, tirzepatide and liraglutide reference standards
- ▸Analytical-method development: HPLC retention profiling and LC-MS confirmation
- ▸Stability testing of lipidated 39-residue peptides in aqueous and lyophilised forms
- ▸Reference material for teaching incretin pharmacology in university-level courses
Handling checklist
- ✓Store lyophilised vials at −20 °C; protect from light and humidity
- ✓Reconstitute with bacteriostatic water; avoid vortexing (foams the peptide)
- ✓Once reconstituted, store at 2–8 °C and use within 28 days
- ✓Verify batch CoA — HPLC ≥98%, mass matches ~4,731 Da, endotoxin low
- ✓Do not administer to humans or animals — research use only
Common research-handling mistakes
Learnt from thousands of researcher orders across our UK labs.
✗ Confusing retatrutide with tirzepatide in supplier catalogues
Fix: Cross-check the LY code (LY3437943 = retatrutide; LY3298176 = tirzepatide) and the receptor profile on the CoA.
✗ Using tap or filtered water for reconstitution
Fix: Only use bacteriostatic water for injection (0.9% benzyl alcohol) or sterile water — never lab DI water.
✗ Storing reconstituted solution at room temperature
Fix: Refrigerate at 2–8 °C immediately after reconstitution; discard after 28 days.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Related questions researchers ask
- Is retatrutide the same molecule as LY3437943?
- What is the correct spelling: retatrutide or retatrutid?
- Is retatrutide a GLP-1 drug?
- Which company makes retatrutide?
- When will retatrutide be FDA approved?
- Is retatrutide legal in the UK?
Frequently asked questions
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubChemPubChem: Retatrutidepubchem.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05869903) — Retatrutide Phase 3 obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-2 (NCT05882045) — Retatrutide in obesity + T2DMclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-3 (NCT05936151) — Retatrutide + established CVDclinicaltrials.gov
- PubMedJastreboff et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity — NEJM 2023 (PMID 37356472)pubmed.ncbi.nlm.nih.gov
- PubMedRosenstock et al., Retatrutide in adults with T2D — Lancet 2023 (PMID 37356473)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Retatrutide (CID 156588324)pubchem.ncbi.nlm.nih.gov
- DrugBankDrugBank · Retatrutide (DB18435)go.drugbank.com
- GuidelineGoogle — Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
Jack Muncaster · Founder, UK Peptides
Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.
More Retatrutide Research articles
- How Retatrutide Differs From First-Generation IncretinsRetatrutide differs from first-generation incretins (exenatide, liraglutide) by activating three receptors and using albumin binding for a longer half-life.
- Retatrutide Storage and Stability (Research Handling)Retatrutide storage: lyophilised vials stable at 2–8°C, reconstituted material for short-term refrigerated use. Handling guidance for research settings.
- Retatrutide Molecular Weight ExplainedRetatrutide molecular weight is approximately 4,731 Da — a 39-residue peptide with fatty-acid conjugation. Why molecular weight matters for peptide research.
- Retatrutide in the Published Literature: Key PapersRetatrutide key published papers: Coskun (Cell Metabolism 2022), Jastreboff (NEJM 2023), Rosenstock (Lancet 2023). Peer-reviewed references summarised.
- What Is the TRIUMPH Trial Programme?TRIUMPH is Eli Lilly's Phase 3 clinical trial programme for retatrutide, covering obesity, type 2 diabetes and related metabolic indications through 2026.
Popular across the research hub
One flagship guide from every other research category — keep exploring.
- GHK-Cu (Copper Peptide)GHK-Cu Mechanism: How the Copper Peptide Works
- TB-500 (Thymosin β4 fragment)TB-500 Mechanism: Actin Sequestration Explained
- BPC-157 (Pentadecapeptide)BPC-157 and the Gastric Juice Origin
- CJC-1295 & IpamorelinCJC-1295 Mechanism: The GHRH Analogue
- Peptide ReferenceResearch Peptides vs Collagen Peptides
- Bacteriostatic WaterBacteriostatic vs Bacteriostatic Saline